Tamtam Try Tamtam free
Thermo Fisher Scientific logo

Thermo Fisher Scientific account plan

Serving science for innovation

At a glance

Thermo Fisher Scientific sells lab instruments, consumables and drug development services, with FY2025 revenues of $44,556 million and about 125,000 staff.

Thermo Fisher Scientific, based in Waltham, Massachusetts, sells instruments, reagents, consumables, lab supplies and outsourced drug development and manufacturing services under brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Patheon and PPD. Its customers are pharma and biotech companies, hospitals and diagnostic labs, universities, government agencies and industrial labs; pharma and biotech is about 60% of revenue. FY2025 revenues were $44,556 million (+4%, organic +2%), with GAAP operating income of $7,746 million and net income attributable of $6,704 million. It had approximately 125,000 colleagues at December 31, 2025, including approximately 14,000 sales personnel. North America generated $23,033 million of 2025 revenue.

Business units

Strategic priorities

Three-pillar growth strategy
High-impact innovation, trusted partner status with customers and the commercial engine, backed by the PPI Business System for productivity.
Long-term growth targets
At the May 2026 Investor Day: 3-6% organic growth with 50-70 bps margin expansion for 2026-2027, and a 7% organic revenue CAGR with 40-50 bps annual margin expansion for 2028-2031+.
AI across science and operations
Collaborations with OpenAI (clinical research) and NVIDIA, and AI inside PPI for customer care, R&D and operations; management says "AI will accelerate science and benefit our industry, we are uniquely positioned to win".
Integrated drug development offering
The Accelerator offering combines CDMO, CRO, clinical endpoints and clinical trial supplies, with biotech customers the main adopters.
U.S. reshoring capacity
Flexible CDMO capacity, outfitting customers' new plants and the Sanofi Ridgefield, NJ sterile fill finish site, against $500B+ of U.S. biopharma reshoring commitments.
M&A-led capital deployment
60-75% of capital to M&A and 25-40% to return of capital over time; more than $70B deployed since 2012.

Latest results

In Q2 2026 (quarter ended June 27, 2026) revenues rose 10% to $11,994 million, with organic growth of 5% and acquisitions adding 5%. Adjusted operating margin was 22.8% (+0.9 pt) and adjusted EPS rose 13% to $6.03. All end markets grew, with pharma and biotech up mid-single digits, academic and government back to low-single-digit growth and China returning to growth. First-half revenues were $22,999 million (+8%). Full-year 2026 guidance was raised to revenue of $47.4 billion-$48.1 billion, organic growth of about 4% and adjusted EPS of $24.93-$25.33.

Investments and deals

Clario acquisition
Acquired on March 24, 2026 for a purchase price of $9,098 million; Clario provides endpoint data solutions for clinical trials (~$1.25B of 2025 revenue) and targets $175M of synergies by year 5.
Solventum filtration and separation
Acquired September 1, 2025 (cash paid $3,944 million); ~$750M of 2025 pro forma revenue and ~$125M of synergies by year five, extending BioProduction.
Microbiology divestiture
Agreed on April 27, 2026 to sell the microbiology business to Astorg for approximately $1.075 billion, closing expected in Q3 2026.
Capex and new facilities
2026 capex expected at $1.9 billion to $2.1 billion, higher for U.S. manufacturing; a U.S. Bioprocess Design Center opened in Massachusetts and filtration capacity is being increased.
Share buybacks
$4.00 billion of stock repurchased in H1 2026, including a $1 billion buyback funded in advance by expected microbiology proceeds.

Challenges and risks

Tariffs and trade
Tariffs and related FX cost over 100 basis points of margin in 2025; Analytical Instruments margin fell 320 basis points to 23%.
Academic and government funding
Academic and government demand declined in 2025 on U.S. customer hesitancy and China macro conditions; Casper expects "a flat to slightly up NIH budget".
China
China declined mid-single digits in 2025, and the 10-K names Chinese regulations requiring the use of local suppliers as a risk.
Indebtedness
Total debt rose to $42,549 million at June 27, 2026 against cash of $4,064 million, and net interest expense nearly doubled to $194 million in Q2.
Pharma services quality and drug pricing policy
Pharma services are "highly exacting and complex", and the Inflation Reduction Act's drug price negotiation could hit customers.

What leadership says

“We are actively deploying AI across the company to further accelerate PPI's impact.”

Marc Casper, Chairman and CEO · Q2 2026 earnings call, 23 July 2026

“We continue to have an active pipeline of M&A opportunities in our highly fragmented industry.”

Marc Casper, Chairman and CEO · Q2 2026 earnings call, 23 July 2026

“the more confidence you have in the research, you wind up doing actually more wet lab experimentation”

Marc Casper, Chairman, President and CEO · Q4 and full-year 2025 earnings call, 29 January 2026

“if you have really relevant innovation, customers get money.”

Marc Casper, Chairman and CEO · Q2 2026 earnings call, 23 July 2026

Where a supplier can help

Manufacturing capacity build-out
Higher 2026 capex for U.S. manufacturing, reshoring CDMO capacity and filtration expansion create demand for equipment, construction and validation suppliers.
AI and productivity in PPI
The push to deploy AI across PPI for customer care, R&D and operations fits AI, automation and digital-twin vendors.
Integration of Clario and Solventum
Synergy targets of $175M (Clario) and ~$125M (Solventum) point to integration, systems consolidation and commercial enablement services.
Trade and supply-chain resilience
Tariff costs and China local-supplier rules open angles for sourcing, trade compliance and low-cost-region manufacturing partners.
Digital commerce for the lab channel
With AI agents and personalised marketing on thermofisher.com and fishersci.com as part of the commercial engine, e-commerce and marketing technology providers have an entry point.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Thermo Fisher Scientific?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Thermo Fisher Scientific

What does Thermo Fisher Scientific do?

It sells lab instruments, reagents, consumables and supplies, diagnostics, and outsourced clinical research and drug manufacturing services to pharma, biotech, healthcare, academic, government and industrial customers.

What was Thermo Fisher Scientific's revenue?

FY2025 revenues were $44,556 million (+4%). 2026 guidance, raised in July 2026, is $47.4 billion-$48.1 billion.

How many employees does Thermo Fisher Scientific have?

Approximately 125,000 colleagues at December 31, 2025, including approximately 14,000 sales personnel.

What is Thermo Fisher Scientific's strategy?

Growth through high-impact innovation, trusted partner status and its commercial engine, productivity from the PPI Business System, and capital deployed mainly through M&A, with a long-term 7% organic growth target.

Who leads Thermo Fisher Scientific?

Marc Casper is Chairman and CEO; Gianluca Pettiti became President and COO and Jim Meyer CFO in March 2026.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)